The experimental investigation of laryngeal cancer growth in vive by recombinant lentivirus of small interference RNA (siRNA) targeting MMP-9.
- Author:
Yanan SUN
1
;
Ming LIU
;
Linli TIAN
;
Yanling GUO
;
Dejun JIN
Author Information
1. Department of Otorhinolaryngology-Head and Neck Surgery, the Second Affiliated Hospital, Harbin Medical University, Harbin, 150086, China. syn2767@yahoo.com.cn
- Publication Type:Journal Article
- MeSH:
Animals;
Cell Line, Tumor;
Gene Silencing;
Humans;
Laryngeal Neoplasms;
metabolism;
pathology;
Lentivirus;
genetics;
Matrix Metalloproteinase 9;
genetics;
metabolism;
Mice;
Mice, Inbred BALB C;
Mice, Nude;
Proliferating Cell Nuclear Antigen;
metabolism;
RNA, Small Interfering;
Transfection;
Xenograft Model Antitumor Assays
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2008;22(24):1129-1131
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the inhibitive role of lentivirus mediated MMP-9 gene silence in the growth of laryngeal cancer xenografts.
METHOD:The nude mouse model of laryngeal squamous carcinoma was established and RNA interference (RNAi) technic was used. Recombinant MMP-9-RNAi-Lentivirus was intratumoral injected while the empty vector lentivirus was taken as control. After the treatment, tumor inhibitive effect was observed and western-blot was used to test the expression of MMP-9 in the xenografts. Finally, the PCNA expression in xenografts were examined with immunohistochemistry to evaluate proliferation change of the Hep-2 cells.
RESULT:The average tumor weight was (1.484 +/- 0.391) g in group treated with MMP-9-RNAi-Lentivirus which was significantly lower than that (2.618 +/- 0.465) g in the control group (P < 0.05). The average tumor volume was (1.177 +/- 0.270) cm3 in group treated with MMP-9-RNAi-Lentivirus which was significantly lower than that (2.034 +/- 0.366) cm3 in the control group (P < 0.05) and the tumor inhibitive rate was 43.32%. Western-blot showed there were 7 cases of xenografts with MMP-9 protein negative expression and the other 3 cases were tested with weak positive expression in the treated group xenografts. Whereas all the 10 cases of xenografts were tested with MMP-9 positive expression in the control group. Immunohistochemistry showed PCNA index in treated group was (55.41 +/- 8.77)% which was obviously lower than that (77.04 +/- 6.91)% in control group (P < 0.01).
CONCLUSION:The growth and proliferation of laryngeal cancer could be inhibited by recombinant MMP-9-RNAi-Lentivirus.
